WHO Launches Guidance on Evidence Generation for New TB Diagnostics
Posted on: Thursday 22nd October, 2026


The World Health Organization (WHO) has released its first-ever Guidance on Evidence Generation (GEG) for New Tuberculosis Diagnostics, providing researchers, developers, funders and policymakers with a roadmap for generating the evidence needed to inform future WHO recommendations on TB diagnostic tests, sample types and testing strategies.
The guidance outlines best-practice approaches for generating robust evidence across a range of areas, including diagnostic accuracy, study design, participant selection, reporting standards, cost-effectiveness, equity, feasibility and acceptability. It also introduces a new analytical framework designed to help researchers map the role of diagnostics across the clinical pathway and align study methods with policy-relevant evidence needs.
Importantly, the guidance seeks to address longstanding gaps in the TB diagnostics evidence base, where studies have often been limited by methodological challenges, inconsistent reporting and the exclusion of populations most likely to benefit from new technologies.
We are pleased to acknowledge the contributions of CRE Associate Investigators Dr Emily Maclean and Professor Mark Nicol, who were members of the Scientific GEG Development Group responsible for supporting the development of this important WHO guidance.
Together with WHO's Target Product Profiles for TB diagnosis and drug-resistance detection, the new guidance aims to strengthen the quality and relevance of evidence generated for novel TB diagnostics, helping accelerate the translation of innovation into policy and practice and supporting faster access to effective diagnostic tools worldwide.
